Monday, May 12, 2014

Zenosense, Inc. (ZENO) and International Stem Cell Corp. (ISCO) Charting Success in the Healthcare Technology Markets

Healthcare technology companies Zenosense Inc. and International Stem Cell Corp. are laying significant groundwork with their proactive research in the areas of MRSA detection and the creation of pluripotent human stem cells from unfertilized oocytes (eggs). Zenosense is a detection device development company based in Valencia, Spain. Its mission is to develop, market and sell an effective MRSA detector, by way of licensed-in technology, for sale to healthcare providers for use in clinical settings. International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.

ZENO recently announced that they have extended their agreement with the Sgenia Group (“Sgenia”) to include cancer sensory devices. Under the terms of the extension, Zenosense has the optional right to fund the development of prospective cancer sensory devices that may be based on the Sgenia technology. Subject to providing funding, the company will have the right to manufacture, market and sell the resulting devices should they be developed.

The company believes the sensory technology and algorithmic processing in development for MRSA detection could, if successful, be applied to certain cancer sensory devices. Some cancers, such as lung and colon, produce volatile organic compounds (“VOCs”) in an individual’s breath in a similar way to patients infected with MRSA. Should the cancer specific pattern of VOCs be identified, ZENO believes that a relatively straightforward modification of a successful MRSA detection technology may enable it to produce a similar device for the detection of certain cancers.

Meanwhile, California based International Stem Cell Corporation, a biotechnology company developing novel stem cell based therapies and biomedical products, announced that it will host a conference call on Wednesday, May 14, 2014 to provide a business update and discuss its financial results for the three months ended March 31, 2014.

Dr. Simon Craw, Executive Vice President and Mr. Jay Novak, Chief Financial Officer of International Stem Cell will host the conference call. To attend the call, please use the dial-in information below:

Date: Wednesday, May 14, 2014
Time: 11:00 a.m. EST
Conference Number (U.S.): 1-877-941-2069
International Dial-In: 1-480-629-9713
Conference ID: 4682485
Webcast: http://public.viavid.com/confirmation/confirmwebcast.php?id=o5aroJyX

A playback of the call will be available from 05/14/14 at 5:00 pm ET until 05/28/14 at 11:59 pm ET. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin number 4682485.

For more information on these companies, visit www.zenosense.net and www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: